|
|
|
|
|
|
|
|
Conclusions Cisplatin/bevacizumab and cisplatin alone neoadjuvant therapy resulted in a significant number of postoperative complications. Specifically, use of expanders/implants may be problematic for patients treated with bev. However, this was a single-arm trial; randomized controlled studies will be needed to determine the optimal use of bevacizumab in the timing of breast cancer surgery.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.